Key Investor Information

This document provides you with key investor information about this Fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this Fund. You are advised to read it so you can make an informed decision about whether to invest.

ECPI Global ESG Med Tech, a subfund of the SICAV BNP PARIBAS EASY

Class "UCITS ETF Capitalisation" - ISIN code LU2365457410
This Fund is managed by BNP PARIBAS ASSET MANAGEMENT Luxembourg, part of the BNP Paribas Group.

Objectives and investment policy

The Fund is an index-tracking passively managed fund.
The Fund seeks to replicate (with a maximum tracking error* of 1%) the performance of the ECPI Global ESG Medical Tech (NR) Index (Bloomberg: GALPHMTN index) (the Index) by investing in the shares issued by companies included in the Index, respecting the Index's weightings (full replication), or in a sample of securities included in the Index (optimised replication). When investing in a sample of shares, the Fund's tracking error may be higher.The Index is composed of companies most active in the sustainable medical technology industry selected on the basis of Environmental, Social and Corporate Governance (ESG) criteria (such as biotechnology, Life sciences tools, recycling, human capital, corporate governance, etc.) and based on their efforts to reduce their exposure to coal and unconventional fossil fuels. As a result, companies involved in sectors with a potentially high negative ESG impact, those subject to significant violations of the UN Global Compact principles and those involved in severe ESG-related controversies are excluded from the Index. The type of approach implemented here is thematic (the index is composed of companies that provide products and services proving concrete solutions to specific environmental and/or social challenges, seeking to benefit from future growth anticipated in these areas while contributing capital to the transition towards a low-carbon, inclusive economy). The extra-financial strategy of the Index may comprise methodological limitations such as the risk related to ESG investment or the Index rebalancing.Further information on the Index, its composition, calculation and rules for periodical review and rebalancing and on the general methodology behind the ECPI indices can be found on www.ecpigroup.com.
*The tracking error is a risk indicator that measures how closely a fund tracks the performance of its reference index.
Incomes are systematically reinvested.
Investors are able to redeem on a daily basis (on Luxembourg bank business days) as described in the prospectus.

Risk and reward profile

Lower risk — Higher risk

Potentially lower rewards — Potentially higher rewards

1	2	3	4	5	**6**	7

- Historical data may not be reliable indication for the future.
- The risk category of a Fund is an indicator but not a target or a guarantee and may shift over time.
- The lowest category does not mean a risk-free investment.
- Why is the Fund in this specific category?
  The risk category is justified by the investment mainly in stocks and shares, the value of which can fluctuate considerably. These fluctuations are often amplified in the short term.
- The higher the risk, the longer the recommended investment horizon.

Other risks materially relevant to the Fund which are not adequately captured by the indicator are described below:

- Counterparty Risk: This risk is associated with the ability of a counterparty in an Over The Counter financial transaction to fulfil its commitments like payment, delivery and reimbursement.
- Operational and Custody Risk: Some markets are less regulated than most of the international markets; hence, the services related to custody and liquidation for the subfund on such markets could be more risky.

For more information on risks, please see the risks section of the Fund's prospectus, which is available at http://www.bnpparibas-am.com.

Charges

The charges you pay are used to pay the Fund's running costs, including the costs of marketing and distribution. These charges reduce the potential growth of your investment.

One-off charges taken before or after you invest	
Primary market (authorised investors)	
Maximum entry charge (not paid to the UCITS)	3.00%
Maximum exit charge (not paid to the UCITS)	3.00%
Secondary market (all investors)	
Maximum entry charge (not paid to the UCITS)	None
Maximum exit charge (not paid to the UCITS)	None
This is the maximum that might be taken out of your money (before the proceeds of your investment are paid out).	
Charges taken from the Fund over each year	
Ongoing charges	0.30% (*)
Charges taken from the fund under specific conditions	
Performance fee	None

The entry and exit charges shown are maximum figures. In some cases you might pay less. You can find this out from your financial adviser.

(*) The **ongoing charges** figure is based on past expenses determined as of December 2023.

This figure may vary from year to year. It excludes:


- Portfolio transaction costs, except in the case of an entry/exit charge paid by the Fund when buying or selling units in another collective investment undertaking.

In addition, the investor's subscription, conversion or redemption order may be subject to an anti-dilution levy (maximum 0.2% for subscription or conversion in, and maximum 0.1% for redemption or conversion out) paid to the sub-fund in order to cover transaction costs.

Conversions not allowed.

For more information about charges, please see the "Fees and Costs" section of the Fund's prospectus, which is available at http://www.bnpparibas-am.com.

Past performance



- Performance figures are shown for shares classes, for which NAV was continuously calculated during the period from 1st January to 31st December.
- Past performance is not an indicator of future results.
- The ongoing charges of the Fund are included in the calculation of past performance. The entry/exit and conversion fees are excluded from the calculation of the past performance.
- The share class came into existence in 2021.
- Past performance has been calculated in EUR.
- Performance returns are based on the net asset value with distribuable income reinvested.

Practical information

- Custodian: BNP PARIBAS, Luxembourg Branch.
- Further information about the Fund including the latest Prospectus, latest published prices of share(s), annual report and half yearly report may be obtained free of charge, in English, from BNP PARIBAS ASSET MANAGEMENT Luxembourg or online at http://www.bnpparibas-am.com.
- Luxembourg tax legislation may have an impact on the personal tax position of the investor.
- Details of the updated remuneration policy (including a description of how the remuneration and benefits are calculated), the identity of the people responsible for granting the remuneration and benefits and the composition of the remuneration committee are available on the website https://www.bnpparibas-am.com/en/footer/remuneration-policy/. A hard copy of the remuneration policy will be available upon request.
- BNP PARIBAS ASSET MANAGEMENT Luxembourg may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the prospectus for the Fund.

This Fund is authorised in Grand Duchy of Luxembourg and regulated by the "Commission de Surveillance du Secteur Financier".
This key investor information is accurate as at 19 February 2024.